IMCR240621C75000
- 0.12
- 0.000.00%
Immunocore Newsroom
Lacklustre Performance Is Driving Immunocore Holdings Plc's (NASDAQ:IMCR) 31% Price Drop
Unfortunately for some shareholders, the Immunocore Holdings plc (NASDAQ:IMCR) share price has dived 31% in the last thirty days, prolonging recent pain. Instead of being rewarded, shareholders who
Express News | Immunocore Announces Randomization of First Patient in the Global, Registrational Phase 3 Clinical Trial Testing Brenetafusp for the Treatment of First-Line Advanced or Metastatic Cutaneous Melanoma
Is Immunocore Holdings (NASDAQ:IMCR) Using Debt Sensibly?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' It's only n
HC Wainwright & Co. Reiterates Buy on Immunocore Hldgs, Maintains $100 Price Target
HC Wainwright & Co. analyst Patrick Trucchio reiterates Immunocore Hldgs with a Buy and maintains $100 price target.
H.C. Wainwright Maintains Immunocore(IMCR.US) With Buy Rating, Maintains Target Price $100
H.C. Wainwright analyst Patrick Trucchio maintains $Immunocore(IMCR.US)$ with a buy rating, and maintains the target price at $100.According to TipRanks data, the analyst has a success rate of 28.9% a
A Quick Look at Today's Ratings for Immunocore(IMCR.US), With a Forecast Between $81 to $92
On Jun 04, major Wall Street analysts update their ratings for $Immunocore(IMCR.US)$, with price targets ranging from $81 to $92.Goldman Sachs analyst Rajan Sharma maintains with a buy rating.Barclays
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Science Applications International Corporation (NASDAQ:SAIC) declined 11% to $119.91 following first-quarter results.SAIC reported a 9% revenue decline year over year in the fiscal first qua
Express News | Guggenheim lowered their target price for Immunocore from $92 to $76.
Express News | Immunocore : Guggenheim Cuts Target Price to $76 From $92
Needham Reiterates Buy on Immunocore Hldgs, Maintains $81 Price Target
Needham analyst Gil Blum reiterates Immunocore Hldgs with a Buy and maintains $81 price target.
Immunocore Hldgs Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/03/2024 68.05% Needham $81 → $81 Reiterates Buy → Buy 05/30/2024 107.47% HC Wainwright & Co. $100 → $10
Buy Rating on Immunocore Holdings Backed by Promising Phase I/II Study Results and Potential T-cell Profile Benefits
Buy Rating Affirmed: Immunocore's Promising Survival Data and High Disease Control Rate in Advanced Melanoma
Immunocore Says New Data Demonstrates Kimmtrak Efficacy for Uveal Melanoma
Kimmtrak clinical data published by Immunocore showed that patients with stable and proven tumor reduction had similar clinical outcomes to patients with partial responses
Kimmtrak clinical data published by Immunocore showed that patients with stable and proven tumor reduction had similar clinical outcomes to patients with partial responses
Immunocore Presents KIMMTRAK Clinical Data Demonstrating That Patients With Stable Disease and Confirmed Tumor Reduction Have Similar Clinical Outcomes to Patients With Partial Response
Immunocore Holdings plc (Nasdaq: IMCR) today presented three posters about KIMMTRAK (tebentafusp-tebn) for the treatment of patients with unresectable or metastatic uveal melanoma (mUM) at the 2024 ASCO (American Society for Clinical Oncology) Annual Meeting.
Immunocore Touts Updated Phase 1 Results for Melanoma Asset Brenetafusp
Immunocore Reports Updated Phase 1 Brenetafusp Data Showing Brenetafusp Was Well Tolerated In Monotherapy And In Combination With Anti-PD1 And Demonstrated A Durable Clinical Benefit
Immunocore Reports Updated Phase 1 Brenetafusp Data Showing Brenetafusp Was Well Tolerated In Monotherapy And In Combination With Anti-PD1 And Demonstrated A Durable Clinical Benefit
Immunocore-monotherapy for advanced cutaneous melanoma, Brenetafusp showed good progression-free survival and ctDNA molecular response
Immunocore-monotherapy for advanced cutaneous melanoma, Brenetafusp showed good progression-free survival and ctDNA molecular response
Express News | Immunocore - Monotherapy Brenetafusp in Late-Line Cutaneous Melanoma Demonstrated Promising Progression Free Survival and Ctdna Molecular Response